Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Social capital components and social support of persons with multiple sclerosis: a systematic review of the literature from 2000 to 2018.

Koutsogeorgou E, Chiesi AM, Leonardi M.

Disabil Rehabil. 2019 Apr 18:1-13. doi: 10.1080/09638288.2019.1597182. [Epub ahead of print]

PMID:
30999768
2.

Onward to 2016.

Jia S, Chiesi A, Kuo WP.

J Circ Biomark. 2016 Jan 28;5:2. doi: 10.5772/62278. eCollection 2016 Jan-Dec. No abstract available.

3.

Integrated isolation and quantitative analysis of exosome shuttled proteins and nucleic acids using immunocapture approaches.

Zarovni N, Corrado A, Guazzi P, Zocco D, Lari E, Radano G, Muhhina J, Fondelli C, Gavrilova J, Chiesi A.

Methods. 2015 Oct 1;87:46-58. doi: 10.1016/j.ymeth.2015.05.028. Epub 2015 Jun 2.

PMID:
26044649
4.

Comparison of serum exosome isolation methods for microRNA profiling.

Rekker K, Saare M, Roost AM, Kubo AL, Zarovni N, Chiesi A, Salumets A, Peters M.

Clin Biochem. 2014 Jan;47(1-2):135-8. doi: 10.1016/j.clinbiochem.2013.10.020. Epub 2013 Oct 29.

PMID:
24183884
5.

Exosomes as intercellular signaling organelles involved in health and disease: basic science and clinical applications.

Corrado C, Raimondo S, Chiesi A, Ciccia F, De Leo G, Alessandro R.

Int J Mol Sci. 2013 Mar 6;14(3):5338-66. doi: 10.3390/ijms14035338.

6.

Exosomes: the ideal nanovectors for biodelivery.

Fais S, Logozzi M, Lugini L, Federici C, Azzarito T, Zarovni N, Chiesi A.

Biol Chem. 2013 Jan;394(1):1-15. doi: 10.1515/hsz-2012-0236. Review.

PMID:
23241589
7.

Serious fatal and nonfatal non-AIDS-defining illnesses in Europe.

Mocroft A, Reiss P, Gasiorowski J, Ledergerber B, Kowalska J, Chiesi A, Gatell J, Rakhmanova A, Johnson M, Kirk O, Lundgren J; EuroSIDA Study Group.

J Acquir Immune Defic Syndr. 2010 Oct;55(2):262-70. doi: 10.1097/QAI.0b013e3181e9be6b.

PMID:
20700060
8.

Proton dynamics in cancer.

Huber V, De Milito A, Harguindey S, Reshkin SJ, Wahl ML, Rauch C, Chiesi A, Pouysségur J, Gatenby RA, Rivoltini L, Fais S.

J Transl Med. 2010 Jun 15;8:57. doi: 10.1186/1479-5876-8-57.

9.

Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?

Reekie J, Mocroft A, Sambatakou H, Machala L, Chiesi A, van Lunzen J, Clumeck N, Kirk O, Gazzard B, Lundgren JD; EuroSIDA Study Group.

AIDS. 2008 Nov 12;22(17):2381-90. doi: 10.1097/QAD.0b013e328317a6eb.

PMID:
18981778
10.

Incidence of abacavir hypersensitivity reactions in euroSIDA.

Bannister WP, Friis-Møller N, Mocroft A, Viard JP, van Lunzen J, Kirk O, Gargalianos P, Bánhegyi D, Chiesi A, Lundgren JD; EuroSIDA Study Group.

Antivir Ther. 2008;13(5):687-96.

PMID:
18771052
11.

Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review.

Nicastri E, Leone S, Angeletti C, Palmisano L, Sarmati L, Chiesi A, Geraci A, Vella S, Narciso P, Corpolongo A, Andreoni M.

J Antimicrob Chemother. 2007 Oct;60(4):724-32. Epub 2007 Aug 21. Review.

PMID:
17715125
12.

Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C.

Mocroft A, Rockstroh J, Soriano V, Kirk O, Viard JP, Caplinskas S, Gasiorowski J, Chiesi A, Phillips AN, Lundgren JD; EuroSIDA Study Group.

Scand J Infect Dis. 2006;38(11-12):1092-7.

PMID:
17148084
13.

Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia.

Mocroft A, Phillips AN, Ledergerber B, Katlama C, Chiesi A, Goebel FD, Knysz B, Antunes F, Reiss P, Lundgren JD.

AIDS. 2006 May 12;20(8):1141-50.

PMID:
16691065
14.

Decline in esophageal candidiasis and use of antimycotics in European patients with HIV.

Mocroft A, Oancea C, van Lunzen J, Vanhems P, Banhegyi D, Chiesi A, Vinogradova E, Maayan S, Phillips AN, Lundgren J; EuroSIDA study group.

Am J Gastroenterol. 2005 Jul;100(7):1446-54.

PMID:
15984964
15.

Clinical outcome after 4 years follow-up of HIV-seropositive subjects with incomplete virologic or immunologic response to HAART.

Nicastri E, Chiesi A, Angeletti C, Sarmati L, Palmisano L, Geraci A, Andreoni M, Vella S; Italian Antiretroviral Treatment Group (IATG).

J Med Virol. 2005 Jun;76(2):153-60.

PMID:
15834865
16.

Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy.

Nicastri E, Angeletti C, Palmisano L, Sarmati L, Chiesi A, Geraci A, Andreoni M, Vella S; Italian Antiretroviral Treatment Group.

AIDS. 2005 Mar 24;19(6):577-83.

PMID:
15802976
17.

Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression.

Phillips AN, Ledergerber B, Horban A, Reiss P, Chiesi A, Kirk O, Mulchany F, Fisher M, Machala L, Lundgren JD; EuroSIDA Study Group.

AIDS. 2004 Sep 3;18(13):1795-804.

PMID:
15316340
18.

Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited.

Moore AL, Kirk O, Johnson AM, Katlama C, Blaxhult A, Dietrich M, Colebunders R, Chiesi A, Lungren JD, Phillips AN; EuroSIDA group.

J Acquir Immune Defic Syndr. 2003 Apr 1;32(4):452-61.

PMID:
12640206

Supplemental Content

Loading ...
Support Center